NewAmsterdam Pharma Corporation - Comprehensive Analysis Report
Summary
NewAmsterdam Pharma Corporation is a late-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly cardiovascular disease (CVD) and other lipid-related conditions. The company's mission is to transform lipid-lowering treatment by advancing innovative therapies that empower individuals with cardiovascular risk to manage their health and live longer, fuller lives. Co-founded in 2019 by Professor Dr. John Kastelein and venture capital firm Forbion, NewAmsterdam Pharma is headquartered in Naarden, the Netherlands, with offices in Miami, United States. The company aims to address the significant unmet need for safe, well-tolerated, and convenient LDL-lowering therapies, especially as an adjunct to statins.
1. Strategic Focus & Objectives
Core Objectives
NewAmsterdam Pharma's core objective is to advance its lead product candidate, obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor. The company aims to establish obicetrapib as a preferred LDL-C lowering therapy, either as a monotherapy or in a fixed-dose combination with ezetimibe, to overcome limitations of current LDL-C lowering treatments in high-risk cardiovascular patients.
Specialization Areas
NewAmsterdam Pharma specializes in the development of novel, oral, non-statin medicines for patients at high risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C). Their unique value proposition lies in their investigational asset, obicetrapib, which utilizes CETP inhibition, a novel mechanism of action for lipid-lowering therapy. Obicetrapib was selected based on its potential to lower LDL-C and reduce cardiovascular risk, leveraging the latest clinical science and genetic research on CETP inhibition.
Target Markets
The primary target market for NewAmsterdam Pharma is patients at high risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), who are not adequately controlled by current treatments. This includes patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH). The company is also exploring obicetrapib's potential in other lipid-driven indications, including Alzheimer's disease.
2. Financial Overview
Funding History
NewAmsterdam Pharma has raised a total funding of $196 million over one round, a Series A round on January 14, 2021. Key investors in this round included Morningside, Forbion, Ascendant BioCapital, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel, Janus Henderson Investors, Medpace, GL Capital, and JVC Investment Partners. This funding supported the initiation and finalization of obicetrapib's Phase 3 clinical development program.
NewAmsterdam Pharma debuted on Nasdaq as a publicly traded company in November 2022, raising $328 million in gross proceeds. In February 2024, the company generated net proceeds of $190 million via an upsized public offering to support obicetrapib's continued development and ongoing commercial readiness. As of December 13, 2024, NewAmsterdam Pharma closed an upsized public offering, raising $479.0 million in gross proceeds with net proceeds of approximately $452.6 million. This offering included 14,667,347 ordinary shares at $24.50 per share and pre-funded warrants to purchase 4,882,653 ordinary shares at $24.4999 per warrant, with underwriters fully exercising their option to purchase an additional 2,550,000 ordinary shares.
As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities of $756.0 million, compared to $834.2 million as of December 31, 2024. As of September 30, 2025, NewAmsterdam Pharma had a trailing 12-month revenue of $35.2 million. In the year 2024, the company recorded annual revenue of $45.56 million, demonstrating a 223.37% growth. For the quarter ending September 30, 2025, revenue was $348,000. The company reported a net loss of $40 million as of March 2025. The company's market capitalization was $4.27 billion with 113 million shares as of October 31, 2025, and its trailing twelve-month earnings per share (EPS) was -$1.61.
3. Product Pipeline
NewAmsterdam Pharma's pipeline is primarily centered around its lead product candidate, obicetrapib, a highly selective CETP inhibitor.
BROADWAY (Phase 3):
Description: Evaluated obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy.
Development Stage: Completed enrollment of over 2,500 patients in July 2023.
Key features and benefits: Reported positive topline data in the fourth quarter of 2024, meeting its primary endpoint with a statistically significant reduction in LDL-C (p<0.0001) at day 84. An observed reduction of 21% in major adverse cardiovascular events favoring obicetrapib at one year was also noted.
BROOKLYN (Phase 3):
Description: Evaluated obicetrapib in 354 patients with HeFH whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy.
Development Stage: Enrollment completed in April 2023.
Key features and benefits: Topline data reported in the third quarter of 2024, showing an LS mean reduction of 36% (p < 0.0001) in LDL-C compared to placebo at day 84. Additional data was presented at the American Heart Association Scientific Sessions 2024.
TANDEM (Phase 3):
Description: Evaluated obicetrapib as a fixed-dose combination with ezetimibe in 407 patients with established ASCVD or multiple risk factors for ASCVD and/or HeFH whose LDL-C is not adequately controlled.
Key features and benefits: The trial met all co-primary endpoints in November 2024, achieving an LS mean reduction of 49% (p < 0.0001) in LDL-C compared to placebo at day 84. Mean and median reductions in LDL-C at day 84 were 52% and 54%, respectively.
PREVAIL (Phase 3 Cardiovascular Outcomes Trial - CVOT):
Description: Evaluating obicetrapib in patients with a history of ASCVD whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy.
Development Stage: Enrollment, exceeding 9,500 patients, was completed in April 2024.
Expected timeline: Topline data is expected in 2026.
VINCENT (Phase 2):
Description: An ongoing single-arm clinical study to evaluate the effects of obicetrapib alone and in combination with evolocumab on lipoprotein (a) (Lp(a)) in patients with mild dyslipidemia.
Expected timeline: The study is expected to complete in the second half of 2025 and enroll 30 patients.
RUBENS (Phase 3):
Description: Evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome requiring additional LDL-C lowering.
Expected timeline: NewAmsterdam plans to initiate this clinical trial in the fourth quarter of 2025.
Marketing Authorization Applications (MAAs) for obicetrapib as a monotherapy and the fixed-dose combination with ezetimibe were accepted for review by the European Medicines Agency (EMA) in August 2025. These submissions were supported by data from the BROADWAY, BROOKLYN, and TANDEM trials.
4. Technology & Innovation
Technology Stack
NewAmsterdam Pharma's technological innovation centers around cholesteryl ester transfer protein (CETP) inhibition as a novel mechanism of action for lipid-lowering therapy. Their lead investigational asset, obicetrapib, is a next-generation, oral, low-dose, and highly selective CETP inhibitor. The development of obicetrapib is guided by the latest clinical science and genetic research in CETP inhibition. Investing in cutting-edge technologies such as AI and machine learning is a strategic priority to enhance drug discovery and development processes.
Proprietary Developments
Obicetrapib is described as a proprietary, next-generation, oral, low-dose, and highly selective CETP inhibitor.
Patents and Intellectual Property
The United States Patent and Trademark Office (USPTO) has issued or allowed a total of nine patents covering obicetrapib and its uses. Notably, a new patent covering the solid form that will be used in the Company's products was issued in June 2024, providing intellectual property protection that extends to July 2043. This patent extends the IP protection for obicetrapib more than nine years beyond the previous second-generation patent expiration in 2034. If approved, this patent will be recognized in the FDA's "Orange Book" as a drug substance patent.
5. Leadership & Management
Executive Team
Dr. Michael Davidson, Chief Executive Officer: Dr. Davidson joined NewAmsterdam Pharma as CEO and Executive Board member in August 2020. He is a leading expert in lipidology and a board-certified physician in internal medicine, cardiology, and clinical lipidology. He was the founder and Chief Medical Officer of Corvidia Therapeutics (acquired by Novo Nordisk in 2020) and co-founding Chief Medical Officer of Omthera Pharmaceuticals (acquired by AstraZeneca in 2013 for $443 million). Dr. Davidson also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. He served as President of the National Lipid Association from 2010 to 2011 and has been named in The Best Doctors in America for many years.
Professor Dr. John Kastelein, Chief Scientific Officer: Prof. Dr. Kastelein is a founder and Chief Scientific Officer of NewAmsterdam Pharma and a member of the Executive Board. He is an Emeritus Professor of Medicine at the Academic Medical Center of the University of Amsterdam. He is a prolific author of research papers in peer-reviewed journals, and his main interest lies in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. He is also president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and a Fellow of the European Society of Cardiology.
Juliette Audet, Chief Business and Strategy Officer: Ms. Audet transitioned into this new role, effective April 1, 2024. She previously served as a Principal at Forbion, joining in 2019, and was a Principal at Novartis Venture Fund, where she observed on the boards of TScan Therapeutics and Annexon Biosciences. Ms. Audet also held a Senior Manager of Strategy role at Novartis AG and spent four years in management consulting at McKinsey and Company focusing on Pharma and Biotech.
Sheng Cui, Chief Manufacturing Officer: (Background not detailed in available information).
Marc Ditmarsch, Chief Development Officer: (Background not detailed in available information).
BJ Jones, Chief Commercial Officer: Appointed in August 2023, his appointment marked the company's evolution into a commercial organization.
Douglas Kling, Chief Operating Officer: (Background not detailed in available information).
Louise Kooij, Chief Accounting Officer: Ms. Kooij assumed the role of Chief Accounting Officer in January 2023, after serving as the company's CFO since May 2020. She has over 25 years of professional experience, including 18 years in finance roles at Sanofi Genzyme and 7 years as a certified auditor at PwC.
Mike Marino, Chief Legal Officer and Corporate Secretary: Mr. Marino joined NewAmsterdam Pharma after serving as Chief Legal Officer at OptiNose, Inc. (2017-2025), and SVP General Counsel at Fibrocell Science, Inc., and NuPathe Inc. (2010-2014). He previously practiced law at Morgan, Lewis & Bockius LLP and WilmerHale LLP.
Maryellen McQuade, Chief People Officer: Ms. McQuade joined in January 2025, bringing over 25 years of HR experience in pharma and biotech, with previous roles at Bristol-Myers Squibb, Novartis Consumer Health, and Novo Nordisk.
Ian Somaiya, Chief Financial Officer: Appointed in October 2024.
Recent Leadership Changes
Juliette Audet assumed the role of Chief Business Officer, effective April 1, 2024, and stepped down from the board of directors.
Ian Somaiya was appointed Chief Financial Officer in October 2024.
In July 2024, Mark C. McKenna and Wouter Joustra were appointed as temporary non-executive directors to the Board of Directors.
Concurrently, Sander Slootweg departed from the Board of Directors, effective July 16, 2024.
The company announced an amended and restated employment agreement with Dr. John Kastelein, Chief Scientific Officer and director, effective July 1, 2025.
6. Talent and Growth Indicators
NewAmsterdam Pharma is a growing company with approximately 68 employees as of December 31, 2024. The company has been actively building out its commercial organization, including the appointment of a Chief Commercial Officer in August 2023. Research and Development (R&D) expenses increased in the first quarter of 2025, primarily due to an increase in personnel costs, including share-based compensation, non-clinical costs related to pipeline expansion, and investments in commercial manufacturing capabilities. This indicates ongoing investment in its workforce and pipeline development. The company champions a culture of inclusivity and integrity, and supports employees in creating innovative therapies.
7. Social Media Presence and Engagement
NewAmsterdam Pharma maintains an active social media presence. Their key messaging emphasizes a "Science-Backed and Patient-Focused" approach, highlighting their commitment to advancing new treatments for cardiovascular disease and lipid-related conditions.
9. Competitive Analysis
NewAmsterdam Pharma operates in a competitive landscape within the cardiovascular disease and lipid-lowering treatment market. Key competitors include established pharmaceutical giants that offer widely used lipid-lowering drugs such as statins and other non-statin therapies. Expected competitors include Amgen, known for Repatha, Regeneron Pharmaceuticals, developer of Praluent, and Novartis, a global pharmaceutical company with a strong presence in cardiovascular health. [cite:# NewAmsterdam Pharma Corporation - Comprehensive Analysis Report
Summary
NewAmsterdam Pharma Corporation is a late-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly cardiovascular disease (CVD) and other lipid-related conditions. The company's mission is to transform lipid-lowering treatment by advancing innovative therapies that empower individuals with cardiovascular risk to manage their health and live longer, fuller lives. Co-founded in 2019 by Professor Dr. John Kastelein and venture capital firm Forbion, NewAmsterdam Pharma is headquartered in Naarden, the Netherlands, with offices in Miami, United States. [cite: 5] The company aims to address the significant unmet need for safe, well-tolerated, and convenient LDL-lowering therapies, especially as an adjunct to statins. [cite: 3, 9]
1. Strategic Focus & Objectives
Core Objectives
NewAmsterdam Pharma's core objective is to advance its lead product candidate, obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor. [cite: 4, 9, 11] The company aims to establish obicetrapib as a preferred LDL-C lowering therapy, either as a monotherapy or in a fixed-dose combination with ezetimibe, to overcome limitations of current LDL-C lowering treatments in high-risk cardiovascular patients. [cite: 11]
Specialization Areas
NewAmsterdam Pharma specializes in the development of novel, oral, non-statin medicines for patients at high risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C). [cite: 3, 4] Their unique value proposition lies in their investigational asset, obicetrapib, which utilizes CETP inhibition, a novel mechanism of action for lipid-lowering therapy. [cite: 35] Obicetrapib was selected based on its potential to lower LDL-C and reduce cardiovascular risk, leveraging the latest clinical science and genetic research on CETP inhibition. [cite: 4, 11]
Target Markets
The primary target market for NewAmsterdam Pharma is patients at high risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), who are not adequately controlled by current treatments. [cite: 3] This includes patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH). [cite: 5] The company is also exploring obicetrapib's potential in other lipid-driven indications, including Alzheimer's disease. [cite: 7]
2. Financial Overview
Funding History
NewAmsterdam Pharma has raised a total funding of $196 million over one round, a Series A round on January 14, 2021. [cite: 1] Key investors in this round included Morningside, Forbion, Ascendant BioCapital, Kaiser Foundation Hospitals, BVF Partners L.P., Population Health Partners, LSP Dementia Fund, Peter Thiel, Janus Henderson Investors, Medpace, GL Capital, and JVC Investment Partners. [cite: 1, 6] This funding supported the initiation and finalization of obicetrapib's Phase 3 clinical development program. [cite: 5, 6]
NewAmsterdam Pharma debuted on Nasdaq as a publicly traded company in November 2022, raising $328 million in gross proceeds. [cite: 5] In February 2024, the company generated net proceeds of $190 million via an upsized public offering to support obicetrapib's continued development and ongoing commercial readiness. As of December 13, 2024, NewAmsterdam Pharma closed an upsized public offering, raising $479.0 million in gross proceeds with net proceeds of approximately $452.6 million. [cite: 3] This offering included 14,667,347 ordinary shares at $24.50 per share and pre-funded warrants to purchase 4,882,653 ordinary shares at $24.4999 per warrant, with underwriters fully exercising their option to purchase an additional 2,550,000 ordinary shares. [cite: 3]
As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities of $756.0 million, compared to $834.2 million as of December 31, 2024. As of September 30, 2025, NewAmsterdam Pharma had a trailing 12-month revenue of $35.2 million. [cite: 4] In the year 2024, the company recorded annual revenue of $45.56 million, demonstrating a 223.37% growth. For the quarter ending September 30, 2025, revenue was $348,000. The company reported a net loss of $40 million as of March 2025. [cite: 13] The company's market capitalization was $4.27 billion with 113 million shares as of October 31, 2025, and its trailing twelve-month earnings per share (EPS) was -$1.61. [cite: 4]
3. Product Pipeline
NewAmsterdam Pharma's pipeline is primarily centered around its lead product candidate, obicetrapib, a highly selective CETP inhibitor. [cite: 4]
BROADWAY (Phase 3):
Description: Evaluated obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy. [cite: 5]
Development Stage: Completed enrollment of over 2,500 patients in July 2023. [cite: 5]
Key features and benefits: Reported positive topline data in the fourth quarter of 2024, meeting its primary endpoint with a statistically significant reduction in LDL-C (p<0.0001) at day 84. An observed reduction of 21% in major adverse cardiovascular events favoring obicetrapib at one year was also noted. [cite: 5]
BROOKLYN (Phase 3):
Description: Evaluated obicetrapib in 354 patients with HeFH whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy.
Development Stage: Enrollment completed in April 2023. [cite: 5]
Key features and benefits: Topline data reported in the third quarter of 2024, showing an LS mean reduction of 36% (p < 0.0001) in LDL-C compared to placebo at day 84. Additional data was presented at the American Heart Association Scientific Sessions 2024. [cite: 5]
TANDEM (Phase 3):
Description: Evaluated obicetrapib as a fixed-dose combination with ezetimibe in 407 patients with established ASCVD or multiple risk factors for ASCVD and/or HeFH whose LDL-C is not adequately controlled. [cite: 5]
Key features and benefits: The trial met all co-primary endpoints in November 2024, achieving an LS mean reduction of 49% (p < 0.0001) in LDL-C compared to placebo at day 84. Mean and median reductions in LDL-C at day 84 were 52% and 54%, respectively. [cite: 5]
PREVAIL (Phase 3 Cardiovascular Outcomes Trial - CVOT):
Description: Evaluating obicetrapib in patients with a history of ASCVD whose LDL-C is not adequately controlled despite maximally tolerated lipid-lowering therapy. [cite: 5]
Development Stage: Enrollment, exceeding 9,500 patients, was completed in April 2024. [cite: 5]
Expected timeline: Topline data is expected in 2026. [cite: 11]
VINCENT (Phase 2):
Description: An ongoing single-arm clinical study to evaluate the effects of obicetrapib alone and in combination with evolocumab on lipoprotein (a) (Lp(a)) in patients with mild dyslipidemia.
Expected timeline: The study is expected to complete in the second half of 2025 and enroll 30 patients.
RUBENS (Phase 3):
Description: Evaluate obicetrapib in combination with ezetimibe in patients with type 2 diabetes or metabolic syndrome requiring additional LDL-C lowering.
Expected timeline: NewAmsterdam plans to initiate this clinical trial in the fourth quarter of 2025.
Marketing Authorization Applications (MAAs) for obicetrapib as a monotherapy and the fixed-dose combination with ezetimibe were accepted for review by the European Medicines Agency (EMA) in August 2025. These submissions were supported by data from the BROADWAY, BROOKLYN, and TANDEM trials.
4. Technology & Innovation
Technology Stack
NewAmsterdam Pharma's technological innovation centers around cholesteryl ester transfer protein (CETP) inhibition as a novel mechanism of action for lipid-lowering therapy. [cite: 35] Their lead investigational asset, obicetrapib, is a next-generation, oral, low-dose, and highly selective CETP inhibitor. [cite: 4, 11] The development of obicetrapib is guided by the latest clinical science and genetic research in CETP inhibition. Investing in cutting-edge technologies such as AI and machine learning is a strategic priority to enhance drug discovery and development processes. [cite: 2, 37]
Proprietary Developments
Obicetrapib is described as a proprietary, next-generation, oral, low-dose, and highly selective CETP inhibitor. [cite: 4, 11, 22]
Patents and Intellectual Property
The United States Patent and Trademark Office (USPTO) has issued or allowed a total of nine patents covering obicetrapib and its uses. [cite: 22] Notably, a new patent covering the solid form that will be used in the Company's products was issued in June 2024, providing intellectual property protection that extends to July 2043. [cite: 14, 15, 22, 23] This patent extends the IP protection for obicetrapib more than nine years beyond the previous second-generation patent expiration in 2034. [cite: 23] If approved, this patent will be recognized in the FDA's "Orange Book" as a drug substance patent. [cite: 14, 15, 22]
5. Leadership & Management
Executive Team
Dr. Michael Davidson, Chief Executive Officer: Dr. Davidson joined NewAmsterdam Pharma as CEO and Executive Board member in August 2020. [cite: 10] He is a leading expert in lipidology and a board-certified physician in internal medicine, cardiology, and clinical lipidology. [cite: 10, 17, 20] He was the founder and Chief Medical Officer of Corvidia Therapeutics (acquired by Novo Nordisk in 2020) and co-founding Chief Medical Officer of Omthera Pharmaceuticals (acquired by AstraZeneca in 2013 for $443 million). [cite: 10, 17, 20, 26] Dr. Davidson also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. [cite: 10, 17] He served as President of the National Lipid Association from 2010 to 2011 and has been named in The Best Doctors in America for many years. [cite: 10, 17]
Professor Dr. John Kastelein, Chief Scientific Officer: Prof. Dr. Kastelein is a founder and Chief Scientific Officer of NewAmsterdam Pharma and a member of the Executive Board. [cite: 10] He is an Emeritus Professor of Medicine at the Academic Medical Center of the University of Amsterdam. [cite: 10] He is a prolific author of research papers in peer-reviewed journals, and his main interest lies in the development of novel therapies for cardiovascular diseases and the genetic basis of dyslipidemia. [cite: 10] He is also president of the Dutch Atherosclerosis Society and the National Scientific Committee on Familial Hypercholesterolemia and a Fellow of the European Society of Cardiology. [cite: 10]
Juliette Audet, Chief Business and Strategy Officer: Ms. Audet transitioned into this new role, effective April 1, 2024. [cite: 25, 31, 32] She previously served as a Principal at Forbion, joining in 2019, and was a Principal at Novartis Venture Fund, where she observed on the boards of TScan Therapeutics and Annexon Biosciences. [cite: 30] Ms. Audet also held a Senior Manager of Strategy role at Novartis AG and spent four years in management consulting at McKinsey and Company focusing on Pharma and Biotech. [cite: 30]
Sheng Cui, Chief Manufacturing Officer: (Background not detailed in available information). [cite: 10]
Marc Ditmarsch, Chief Development Officer: (Background not detailed in available information). [cite: 10]
BJ Jones, Chief Commercial Officer: Appointed in August 2023, his appointment marked the company's evolution into a commercial organization. [cite: 5, 10]
Douglas Kling, Chief Operating Officer: (Background not detailed in available information). [cite: 10]
Louise Kooij, Chief Accounting Officer: Ms. Kooij assumed the role of Chief Accounting Officer in January 2023, after serving as the company's CFO since May 2020. [cite: 12, 18, 19] She has over 25 years of professional experience, including 18 years in finance roles at Sanofi Genzyme and 7 years as a certified auditor at PwC. [cite: 12, 18, 19]
Mike Marino, Chief Legal Officer and Corporate Secretary: Mr. Marino joined NewAmsterdam Pharma after serving as Chief Legal Officer at OptiNose, Inc. (2017-2025), and SVP General Counsel at Fibrocell Science, Inc., and NuPathe Inc. (2010-2014). He previously practiced law at Morgan, Lewis & Bockius LLP and WilmerHale LLP. [cite: 10]
Maryellen McQuade, Chief People Officer: Ms. McQuade joined in January 2025, bringing over 25 years of HR experience in pharma and biotech, with previous roles at Bristol-Myers Squibb, Novartis Consumer Health, and Novo Nordisk. [cite: 10]
Ian Somaiya, Chief Financial Officer: Appointed in October 2024. [cite: 10]
Recent Leadership Changes
Juliette Audet assumed the role of Chief Business Officer, effective April 1, 2024, and stepped down from the board of directors. [cite: 25, 31, 32]
Ian Somaiya was appointed Chief Financial Officer in October 2024. [cite: 10]
In July 2024, Mark C. McKenna and Wouter Joustra were appointed as temporary non-executive directors to the Board of Directors.
Concurrently, Sander Slootweg departed from the Board of Directors, effective July 16, 2024.
The company announced an amended and restated employment agreement with Dr. John Kastelein, Chief Scientific Officer and director, effective July 1, 2025.
6. Talent and Growth Indicators
NewAmsterdam Pharma is a growing company with approximately 68 employees as of December 31, 2024. [cite: 16] The company has been actively building out its commercial organization, including the appointment of a Chief Commercial Officer in August 2023. [cite: 5] Research and Development (R&D) expenses increased in the first quarter of 2025, primarily due to an increase in personnel costs, including share-based compensation, non-clinical costs related to pipeline expansion, and investments in commercial manufacturing capabilities. [cite: 27] This indicates ongoing investment in its workforce and pipeline development. The company champions a culture of inclusivity and integrity, and supports employees in creating innovative therapies. [cite: 21]
7. Social Media Presence and Engagement
NewAmsterdam Pharma maintains an active social media presence. Their key messaging emphasizes a "Science-Backed and Patient-Focused" approach, highlighting their commitment to advancing new treatments for cardiovascular disease and lipid-related conditions. [cite: 8, 35]
9. Competitive Analysis
NewAmsterdam Pharma operates in a competitive landscape within the cardiovascular disease and lipid-lowering treatment market. [cite: 2] Key competitors include established pharmaceutical giants that offer widely used lipid-lowering drugs such as statins and other non-statin therapies. [cite: 2] Expected competitors include Amgen, known for Repatha, Regeneron Pharmaceuticals, developer of Praluent, and Novartis, a global pharmaceutical company with a strong presence in cardiovascular health. [cite:
